Subscribe Now Subscribe Today
Research Article
 

An Overview of Mitochondrial Toxicity of Nucleoside Reverse Transcriptase Inhibitors Associated with HIV Therapy



C.N. Fokunang , J. Hitchcock , F. Spence , E.A. Tembe-Fokunang , J. Burkhardt , L. Levy and C. George
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

Mitochondria provide energy required for normal cell function and thus tissue function by producing Adenosine Triphosphate (ATP) via oxidative phosphorylation. They also regulate a number of other cellular processes, including apoptosis. Nucleoside Reverse Transcriptase Inhibitors (nRTIs) remain the cornerstone of Highly Active Antiretroviral Therapy (HAART) combination regimens. However, it has been known for some time that these agents have the potential to cause varied side effects, many of which are thought to be due to their effects on mitochondria. nRTIs can affect the function of this enzyme and this may lead to depletion of mitochondrial DNA or qualitative changes. Various clinical and in vitro studies have shown that nRTIs are associated with mitochondrial dysfunction in different tissues, although the weight of evidence is limited in many cases. The heterogeneity in the tissues affected by the different drugs raises interesting questions and possible explanations include differential distribution or activation of these agents. This study gives an overview of the major recognised toxicities associated with nRTI use in Human Immunodeficiency syndrome (HIV) therapy and evidence for mitochondrial dysfunction in these complications.

Services
Related Articles in ASCI
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

C.N. Fokunang , J. Hitchcock , F. Spence , E.A. Tembe-Fokunang , J. Burkhardt , L. Levy and C. George , 2006. An Overview of Mitochondrial Toxicity of Nucleoside Reverse Transcriptase Inhibitors Associated with HIV Therapy. International Journal of Pharmacology, 2: 152-162.

DOI: 10.3923/ijp.2006.152.162

URL: https://scialert.net/abstract/?doi=ijp.2006.152.162

REFERENCES

1:  Lewis, W., J.F. Simpson and R.R. Meyer, 1994. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circulat. Res., 74: 344-348.
Direct Link  |  

2:  Moyle, G.J., 2004. Mitochondrial toxicity: Myths and facts. J. HIV Ther., 9: 45-47.
PubMed  |  

3:  Moyle, G.J. and M. Sadler, 1998. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Saf., 19: 481-494.
Direct Link  |  

4:  Lopez, S., O. Miro, E. Martinez and E. Pedrol, 2004. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir. Ther., 9: 47-55.
Direct Link  |  

5:  Lecrenier, N. and F. Foury, 2000. New features of mitochondrial DNA replication system in yeast and man. Genetics, 246: 37-48.
Direct Link  |  

6:  Pinti, M., L. Troiano, M. Nasi and R. Ferraresi, 2003. Hepatoma Hep G2 cells as a model for in vitro studies on mitochondrial toxicity of antiviral drugs: which correlation with the patients? J. Biol. Regul. Homeost. Agents, 17: 166-171.
Direct Link  |  

7:  White, A.J., 2001. Mitochondria toxicity and HIV therapy. Sex Trans. Inform., 77: 158-173.
Direct Link  |  

8:  Lee, H., J. Hanes and K.A. Johnson, 2003. Toxicity of nucleoside analogues used to treat AIDs and the selectivity of mitochondrial DNA polymerase. Biochemistry, 42: 14711-14719.
Direct Link  |  

9:  Jacotot, E., K.F. Ferri, C. El-Hamel, C. Brennera and S. Druillennecb et al., 2001. Control of mitochondrial membrane permeabilisation by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. J. Exp. Med., 193: 509-519.
Direct Link  |  

10:  Lewis, W., 2003. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions. Antiviral Res., 58: 189-197.
CrossRef  |  

11:  Ogedegbe, A.E.O., D.L.Thomas and A.M. Diehl, 2003. Hyperlactataemia syndrome associated with HIV therapy. Lancet, 3: 329-337.
Direct Link  |  

12:  Leonard, J.V. and A.H.V. Schapira, 2000. Mitochondrial respiratory chain disorders I: Mitochondrial DNA defects. Lancet, 355: 299-304.
Direct Link  |  

13:  Mandavilli, B.S., J. Santos and B. van Houten, 2002. Mitochondrial DNA repair and aging. Mutat.. Res., 509: 127-151.
Direct Link  |  

14:  Rossi, L., S. Serafini and G.F. Schiavano, 1999. Metabolism, mitochondrial uptake and toxicity of 2', 3-dideoxycytidine. Biochem. J., 344: 915-920.
Direct Link  |  

15:  Ballinger, S.W., B. van Houten and C.A. Coklin, 1999. Hydrogen peroxide causes significant mitochondrial DNA damage in human RPE cells. Exp. Eye Res., 68: 765-772.
Direct Link  |  

16:  Fleischer, R., D. Boxwell and K.E. Sherman, 2004. Nucleoside analogues and mitochondrial toxicity. Clin. Infect. Dis., 38: 79-80.
Direct Link  |  

17:  Benbrik, E., P. Chariot, S. Bonavaud, M. Ammi-Said and E. Frisdal et al., 1997. Cellular and mitochondrial toxicity of zidovudine AZT, didanosine ddI and zalcitabine ddC on cultured human muscle cells. J. Neurol. Sci., 149: 19-25.
Direct Link  |  

18:  Bishop, J.B., Y. Tani, K. Witt, J.A. Johnson and S. Peddada, 2004. Mitochondria damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol. Sci., 81: 512-517.
Direct Link  |  

19:  Taanman, J.W., 1999. The mitochondrial genome: Structure, transcription, translation and replication. Biochim. Biophys. Acta, 1410: 103-123.
Direct Link  |  

20:  Adkins, J.C., D.H. Peters and D. Faulds, 1997. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs, 53: 1054-1080.
PubMed  |  

21:  Cherrington, J.M., S.J.W. Allen and N. Bischofberger, 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases alpha, beta and gamma. Antiviral Chem. Chemother., 6: 217-221.

22:  Antoniades, C., C. Macdonald, A. Knisely, C. Taylor and S. Norris, 2004. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl., 10: 699-702.
Direct Link  |  

23:  Ropp, P.A. and W.C. Copeland, 1996. Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics, 36: 449-458.
Direct Link  |  

24:  Davis, A.F., P.A. Ropp and D.A. Clayton, 1996. Mitochondrial DNA polymerase gamma is expressed and translated in the absence of mitochondrial DNA maintenance and replication. Nucl. Acids Res., 24: 2753-2759.
Direct Link  |  

25:  Glesby, M.J., 2002. Overview of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. Perspect Int. AIDS Soc. USA., 10: 42-46.

26:  Rasmussen, L.J. and K.K. Singh, 1998. Genetic Integrity of the Mitochondrial Genome. In: Mitochondrial DNA Mutations in Aging, Disease and Cancer, Singh, K.K. (Ed.). Springer, New York, pp: 115-127

27:  De la Asuncion, J.G., N. del Olmo, M.L. Sastre, A. Millan and A. Pellin, 1998. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J. Clin. Invest., 102: 4-9.
Direct Link  |  

28:  Carr, A., J. Miller, M. Law and D.A. Cooper, 2000. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS, 14: F25-F32.
Direct Link  |  

29:  Brinkman, K., J.A. Smeitink J.A. Romijn and P. Reiss, 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet, 354: 1112-1115.
PubMed  |  Direct Link  |  

30:  Chiappini, F., E. Teiccher, R. Saffroy and P. Pham, 2004. Prospoective evaluation of blood concentration of mitochondrial DNA as marker of toxicity in 157 consecutively recruited untreated or HAART- treated HIV-positive patients. Lab. Invest., 84: 908-914.

31:  Wright, G.E. and N.C. Brown, 1990. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmacol. Ther., 47: 447-497.

32:  Shaw-Reid, C.A., B. Feuston, V. Munshi, K. Getty and J. Krueger et al., 2005. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry, 44: 1595-1606.
Direct Link  |  

33:  Srivastava, D.K., C.L. Tendler and D. Milani,. 2001. The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme β-polymerase. AIDS, 15: 433-440.
Direct Link  |  

34:  Cheng, Y.C., W.Y. Gao and C.H.Chen, 1990. DNA polymerases versus HIV reverse transcriptase in AIDS therapy. Ann. N. Y. Acad. Sci., 616: 217-223.

35:  Lori, F., L.M. Kelly and J. Lisziewicz, 2004. Safety of hydroxyurea in trhe treatment of HIV infection. Exp. Opin. Drug. Saf., 3: 279-288.

36:  Daggett, T.L., C.M. Pearce and S.M.C. Robinson, 2006. A comparison of three land-based containment systems for use in culturing green sea urchins, Strongylocentrotus droebachiensis (Muller) (Echinodermata: Echinoidea). Aquacult. Res., 37: 339-350.
Direct Link  |  

37:  Ter Hofstede, H.J., H.L. Willems and P.P. Koopmans, 2004. Serum L-lactate and pyruvate in HIV-infected patients and with and without presumed nRTI-related adverse events compared to healthy volunteers. J. Clin. Virol., 29: 44-50.

38:  Cui, L., L. Locatelli and M.Y. Xie, 1997. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J. Pharmacol. Exp. Ther., 280: 1228-1234.
Direct Link  |  

39:  Kakuda, T.N., 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther., 22: 685-708.
Direct Link  |  

40:  Martin, J.L., C.E. Brown and N. Matthews-Davis, 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother., 38: 2743-2749.
Direct Link  |  

41:  Lipshultz, S.E., E.J. Orav and S.P. Sanders, 1992. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N. Engl. J. Med., 327: 1260-1265.

42:  Lipshultz, S.E., 2001. Absence of cardiac toxicity of zidovudine in infants-reply. N. Engl. J. Med., 344: 458-485.

43:  Tornevik, Y., B. Ullman and J. Balzarini, 1995. Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate AZTMP levels, whereas anti-human immunodeficiency virus HIV activity correlates with 3'-azidothymidine-5'-triphosphate AZTTP levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol., 49: 829-837.

44:  Lipshultz, S.E., 1998. Dilated cardiomyopathy in HIV-infected patients. N. Engl. J. Med., 339: 1153-1155.

45:  Bridges, E.G., Z. Jiang and Y.C. Cheng, 1999. Characterization of a dCTP transport activity reconstituted from human mitochondria. J. Biol. Chem., 274: 4620-4625.
Direct Link  |  

46:  Dutschman, G.E., E.G. Bridges and S.H. Liu, 1998. Metabolism of 2', 3-dideoxy-2',3'-didehydro-β-L(B)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother., 42: 1799-1804.

47:  Dalakas, M.C., I. Illa and G.H. Pezeshkpour, 1990. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med., 322: 1098-1105.

48:  Brinkman, K., H.J.M. Ter-Hofstede, D.M. Burger, J.A. Smeitink and P.P. Koopmans, 1998. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS, 12: 1735-1744.
PubMed  |  Direct Link  |  

49:  Lewis, W. and M.C. Dalakas, 1995. Mitochondrial toxicity of antiviral drugs. Nat. Med., 1: 417-422.
CrossRef  |  PubMed  |  

50:  Freiman, J.P., K.E. Helfert and M.R. Hamrell, 1993. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS, 7: 379-385.

51:  Moses, A., J. Nelson and J.G.C. Bagby, 1998. Review article: the influence of human immunodeficiency virus-1 on hematopoiesis. Blood, 91: 1479-1495.
Direct Link  |  

52:  Wilde, M.I. and H.D. Langtry, 1993. Zidovudine: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs, 46: 515-578.
Direct Link  |  

53:  Walker, U.A., M. Bickel and S.I. Volksbeck, 2000. Decrease of mitochondria DNA content in adipose tissie of HIV-1 infected patients treated with nRTIs. Antivir. Ther., 5: 5-6.

54:  Hermans, J.S. and P.J. Easterbrook, 2001. The metabolic toxicities of antiretroviral therapy. Int. J. STD AIDS, 12: 555-562.
Direct Link  |  

55:  Moquattash, S., J.D. Lutton and G. Rosenthal, 1997. Effect of blood substitute, recombinant hemoglobin, on in vitro hematopoietic recovery from AZT toxicity. Acta Haematol., 98: 76-82.
Direct Link  |  

56:  Henry, D.H., G.N. Beall and C.A. Benson, 1992. Recombinant human erythropoietin in the treatment of anaemia associated with human immunodeficiency virus HIV infection and zidovudine therapy. Ann. Int. Med., 117: 739-748.
Direct Link  |  

57:  Chariot, P. and R. Gherardi, 1995. Myopathy and HIV infection. Curr. Opin. Rheumatol., 7: 497-502.
Direct Link  |  

58:  Simpson, D.M., K.A. Citak and E. Godfrey, 1993. Myopathies associated with human immunodeficiency virus and zidovudine: Can their effects be distinguished? Neurology, 43: 971-976.

59:  Simpson, D.M., D.A. Katzenstein and M.D. Hughes, 1998. Neuromuscular function in HIV infection: Analysis of a placebo-controlled combination antiretroviral trial. AIDS, 12: 2425-2432.
Direct Link  |  

60:  Masanes, F., A. Barrientos and M. Cebrian, 1998. Clinical, histological and molecular reversibility of zidovudine myopathy. J. Neurol. Sci., 159: 226-228.
Direct Link  |  

61:  Lewis, W., I.L. Grupp and G. Grupp, 2000. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab. Invest., 80: 187-197.
Direct Link  |  

62:  Barbaro, G., G. di Lorenzo and B. Grisorio, 1998. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N. Engl. J. Med., 339: 1093-1099.

63:  Di Mauro, S. and M. Hirano, 1998. Mitochondria and heart disease. Curr. Opin. Cardiol., 13: 190-197.
Direct Link  |  

64:  Yunis, N.A. and V.E. Stone, 1998. Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 18: 145-154.
Direct Link  |  

65:  Herskowitz, A., S.B. Willoughby and K.L. Baughman, 1992. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases. Ann. Int. Med., 116: 311-313.

66:  Wulff, E.A., A.K. Wang and D.M. Simpson, 2000. HIV-associated peripheral neuropathy. Drugs, 59: 1251-1260.

67:  Lonergan, J.T., R.E. Barber and W.C. Mathews, 2003. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS, 17: 2495-2499.
Direct Link  |  

68:  Carr, A., J. Miller, J.A. Eisman and D.A. Cooper, 2001. Osteopenia in HIV-infected men: Association with asymptomatic lactic academia and lower weight pre-antiretroviral therapy. AIDS, 13: 703-709.

69:  Monier, P.L. and R. Wilcox, 2004. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1 infected adults. Am. J. Med. Sci., 328: 48-56.
Direct Link  |  

70:  John, M., D. Nolan and S.A. Mallal, 2001. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther., 6: 9-20.
Direct Link  |  

71:  Manfredi, R., L. Calza and F. Chiodo, 2002. A life-long antiretroviral treatment of congenital HIV disease, associated with a mixed fat redistribution syndrome and osteopenia already occurred during pre-pubertal age. Int. J. STD AIDS, 13: 504-507.
Direct Link  |  

72:  Springer, S.A. and F.L. Altice, 2003. Human immunodeficiencyvirus infection with granulocytic ehrlichiosis complicated by symptomatic lactic acidosis. Clin. Infect. Dis., 36: 162-164.

73:  Gerard, Y., L. Maulin and Y. Yazdanpanah, 2000. Symptomatic hyperlactatemia: An emerging complication of antiretroviral therapy. AIDS, 14: 2723-2730.

74:  Sheng, W.H., S.M. Hsieh, S.C. Lee and M.Y. Cheng, 2004. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan. Int. J. STD AIDS, 15: 249-253.

75:  Moreno, A., C. Quereda, L. Moreno and M.J. Perez-Elias, 2004. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinnfected patients receiving ribavirin. Antiviral Ther., 9: 133-138.

76:  Gervasoni, C., A.L. Ridolfo, G. Trifiro, S. Santambrogio and G. Norbiato et al., 1999. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS, 13: 465-471.
Direct Link  |  

77:  Saint-Marc, T. and J.L. Touraine, 1999. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS, 13: 2188-2189.
Direct Link  |  

78:  Bogner, J.R., G.M. Michl and W. Neuhofer, 2000. No difference in lipodystrophy incidence in stavudine versus zidovudine nucleoside backbone blinded evaluation in a cohort on first line HAART. Antiviral Ther., 5: 55-55.

79:  Villarroya, F., P. Domingo and M. Giralt, 2005. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: The adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol. Sci., 26: 88-93.

80:  Kakuda, T.N., R.C. Brundage and P.L. Anderson,. 1999. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS, 13: 2311-2312.

81:  Clark, A., 2000. Improvement of facial lipoatrophy after substitution of stavudine. Antiviral Ther., 5: 73-74.

82:  Brinkman, K. and H.J. Ter-Hofstede, 1999. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options. AIDS Rev., 1: 140-146.

83:  Law, M., S. Emery, M. French, A. Carr, J. Chuah and D. Cooper, 2000. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy. Antiviral Ther., 5: 18-18.
Direct Link  |  

84:  Moyle, G.J. and A. Carr, 2002. HIV-associated lipodystrophy, metabolic complications and antiretroviral toxicities. HIV Clin. Trials, 3: 89-98.

85:  Paice, J.A., S. Shott and F. Oldenburg, 2000. Efficacy of a vibratory stimulus for the relief of HIV-associated neuropathic pain. Pain, 84: 291-296.

86:  Ho, H.T. and M.J. Hitchcock, 1989. Cellular pharmacology of 2', 3=-dideoxy-2', 3=-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother., 33: 844-849.

87:  Heath, K.V., J.S. Montaner, G. Bondy, J. Singer, M.V. O'Shaughnessy and R.S. Hogg, 2003. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr. Drug. Targets, 4: 13-22.

88:  Smith, K.Y., 2002. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J. Infect. Dis., 185: 123-127.
Direct Link  |  

89:  Hermans, P., W. Rozenbaum, A. Jou, F. Castelli and J. Borleffs et al., 1996. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS, 10: 1627-1633.
Direct Link  |  

90:  Geene, D., P. Sudre, D. Anwar, C. Goehring, A. Saaidia and B. Hirschel, 2000. Causes of macrocytosis in HIV-infected patients not treated with zidovudine. J. Infect., 40: 160-163.
Direct Link  |  

91:  Dolce, V., G. Fiermonte, M.J. Runswick, F. Palmieri and J.E. Walker, 2001. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc. Natl. Acad. Sci. USA., 98: 2284-2288.
Direct Link  |  

92:  Montessori, V., N. Press, M. Harris, L. Akagi and J.S. Montaner, 2004. Adverse effects of antiretroviral therapy for HIV infection. Can. Med. Assoc. J., 170: 229-238.
PubMed  |  Direct Link  |  

93:  Simpson, D.M. and M. Tagliati, 1995. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 9: 153-161.
Direct Link  |  

94:  Khan, J., S. Lagakos, M. Wulfsohn, D. Cherng and M. Miller et al., 1999. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. J. Am. Med. Assoc., 282: 2305-2312.
Direct Link  |  

95:  Paulik, M., M. Lancaster and D. Croom, 2000. Anti-oxidants rescue nRTI-induce metabolic changes in AKR/J mice. Antivir. Ther., 5: 6-7.

96:  Moore, R.D., W.E. Wong and J.C. Keruly, 2000. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS, 14: 273-278.
Direct Link  |  

97:  Niaudet, P., 1998. Mitochondria disorders and the kidney. Arch. Dis. Child, 78: 383-393.
Direct Link  |  

98:  Crowther, M.A., W. Callaghan and A.B. Hodsman, 1993. Dideoxyinosine-associated nephrotoxicity (letter). AIDS, 7: 131-132.

99:  Brinkman, K. and T.N. Kakuda, 2000. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term antiretroviral therapy. Curr. Opin. Infect. Dis., 19: 5-11.

100:  Moon, S.K., L.J. Thompson, N. Madamanchi, J. Ballinger and J. Papaconstantinou et al., 2001. Aging, oxidative stress and proliferative capacity in cultured mouse aortic smooth muscle cells. Am. J. Physiol. Heart Cir. Physiol., 280: 2779-2788.

101:  Morris, A.A.M., S. Baudouin and M.H. Snow, 2001. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS, 15: 140-141.

102:  Dassopoulos, T. and E.D. Ehrenpreis, 1999. Acute pancreatitis in human immunodeficiency virus-infected patients: A review. Am. J. Med., 107: 78-84.

103:  John, M., C. Moore, I.R. James, D. Nolan and R.P. Upton et al., 2001. Chronic hyperlactaemia in HIV-infected patients taking antiretroviral therapy. AIDS, 15: 717-723.

104:  Leonard, J.V. and A.H.V. Schapira, 2000. Mitochondrial respiratory chain disorders. II: Neurodegenerative disorders and nuclear gene defects. Lancet, 355: 389-394.
Direct Link  |  

105:  Shaer, A.J. and A. Rastegar, 2000. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome a case report and review of the literature. Am. J. Nephrol., 20: 332-338.
Direct Link  |  

106:  Shoffner, J.M. and D.C. Wallace, 1992. Mitochondrial genetics: Principles and practice. Am. J. Hum. Genet., 51: 1179-1186.

107:  Simpson, D.M., P. Slasor, U. Dafni, J. Berger, M.A. Fischl and C. Hall, 1997. Analysis of myopathy in a placebo-controlled zidovudine trial. Muscle Nerve, 20: 382-385.
Direct Link  |  

108:  Harris, M., A. Tesiorowski and K. Chan, 2000. Lactic acidosis complicating antiretroviral therapy: Frequency and correlates. Antiviral Ther., 5: 31-31.

109:  Nolan, D. and F. Christiansen, 2003. 4th international workshop on adverse drug reactions and lipodystrophy HIV. Exp. Opin. Drug. Saf., 2: 95-101.
Direct Link  |  

110:  Mallal, S.A., M. John, C.B. Moore, I.R. James and E.J. McKinnon, 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS, 14: 1309-1316.
Direct Link  |  

111:  Blasi, E., B. Colombari C.F. Orsi and M. Pinti, 2004. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Crytococcus neoform. FEMS Immunol. Med. Microbiol., 42: 187-195.

©  2021 Science Alert. All Rights Reserved